These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 20801656)

  • 1. A new NF-κB inhibitor based on the amino-epoxyquinol core of DHMEQ.
    Saitoh T; Shimada C; Takeiri M; Shiino M; Ohba S; Obata R; Ishikawa Y; Umezawa K; Nishiyama S
    Bioorg Med Chem Lett; 2010 Oct; 20(19):5638-42. PubMed ID: 20801656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficient synthesis of (+/-)-parasitenone, a novel inhibitor of NF-kappaB.
    Saitoh T; Suzuki E; Takasugi A; Obata R; Ishikawa Y; Umezawa K; Nishiyama S
    Bioorg Med Chem Lett; 2009 Sep; 19(18):5383-6. PubMed ID: 19666224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting of nuclear factor kappaB Pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo.
    Matsumoto G; Namekawa J; Muta M; Nakamura T; Bando H; Tohyama K; Toi M; Umezawa K
    Clin Cancer Res; 2005 Feb; 11(3):1287-93. PubMed ID: 15709200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of macrophage activation and phagocytosis by a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin.
    Suzuki E; Umezawa K
    Biomed Pharmacother; 2006 Nov; 60(9):578-86. PubMed ID: 16978829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
    Takatsuna H; Asagiri M; Kubota T; Oka K; Osada T; Sugiyama C; Saito H; Aoki K; Ohya K; Takayanagi H; Umezawa K
    J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of inflammatory mediator secretion by (-)-DHMEQ in mouse bone marrow-derived macrophages.
    Suzuki E; Sugiyama C; Umezawa K
    Biomed Pharmacother; 2009 Jun; 63(5):351-8. PubMed ID: 18635336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of cancer cachexia by a novel nuclear factor {kappa}B inhibitor in prostate cancer.
    Kuroda K; Horiguchi Y; Nakashima J; Kikuchi E; Kanao K; Miyajima A; Ohigashi T; Umezawa K; Murai M
    Clin Cancer Res; 2005 Aug; 11(15):5590-4. PubMed ID: 16061877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of inflammatory cytokine secretion from mouse microglia cells by DHMEQ, an NF-kappaB inhibitor.
    Takatsuna H; Morita S; Nagatsu T; Sawada M; Umezawa K
    Biomed Pharmacother; 2005 Jul; 59(6):318-22. PubMed ID: 15932789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting NF-kappaB and induction of apoptosis by novel NF-kappaB inhibitor dehydroxymethylepoxyquinomicin (DHMEQ) in Burkitt lymphoma cells.
    Kimura N; Miyakawa Y; Kohmura K; Umezawa K; Ikeda Y; Kizaki M
    Leuk Res; 2007 Nov; 31(11):1529-35. PubMed ID: 17466373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DHMEQ, a novel NF-kappaB inhibitor, induces apoptosis and cell-cycle arrest in human hepatoma cells.
    Nishimura D; Ishikawa H; Matsumoto K; Shibata H; Motoyoshi Y; Fukuta M; Kawashimo H; Goto T; Taura N; Ichikawa T; Hamasaki K; Nakao K; Umezawa K; Eguchi K
    Int J Oncol; 2006 Sep; 29(3):713-9. PubMed ID: 16865289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Possible role of peritoneal NF-κB in peripheral inflammation and cancer: lessons from the inhibitor DHMEQ.
    Umezawa K
    Biomed Pharmacother; 2011 Jul; 65(4):252-9. PubMed ID: 21723080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of histidine decarboxylase in macrophages inhibited by the novel NF-kappaB inhibitor (-)-DHMEQ.
    Suzuki E; Ninomiya Y; Umezawa K
    Biochem Biophys Res Commun; 2009 Feb; 379(2):379-83. PubMed ID: 19103154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), on growth, apoptosis, gene expression, and chemosensitivity in head and neck squamous cell carcinoma cell lines.
    Ruan HY; Masuda M; Ito A; Umezawa K; Nakashima T; Yasumatsu R; Kuratomi Y; Yamamoto T; Weinstein IB; Komune S
    Head Neck; 2006 Feb; 28(2):158-65. PubMed ID: 16355386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inactivation of NF-kappaB components by covalent binding of (-)-dehydroxymethylepoxyquinomicin to specific cysteine residues.
    Yamamoto M; Horie R; Takeiri M; Kozawa I; Umezawa K
    J Med Chem; 2008 Sep; 51(18):5780-8. PubMed ID: 18729348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor effect of a novel nuclear factor-kappa B activation inhibitor in bladder cancer cells.
    Horiguchi Y; Kuroda K; Nakashima J; Murai M; Umezawa K
    Expert Rev Anticancer Ther; 2003 Dec; 3(6):793-8. PubMed ID: 14686701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor effects of the novel NF-kappaB inhibitor dehydroxymethyl-epoxyquinomicin on human hepatic cancer cells: analysis of synergy with cisplatin and of possible correlation with inhibition of pro-survival genes and IL-6 production.
    Poma P; Notarbartolo M; Labbozzetta M; Sanguedolce R; Alaimo A; Carina V; Maurici A; Cusimano A; Cervello M; D'Alessandro N
    Int J Oncol; 2006 Apr; 28(4):923-30. PubMed ID: 16525642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preparation of radioactively labeled dehydroxymethyl-epoxyquinomicin, an NF-kappa B function inhibitor.
    Chaicharoenpong C; Kato K; Umezawa K
    Drugs Exp Clin Res; 2003; 29(1):1-3. PubMed ID: 12866358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NF-kappaB inhibitor dehydroxymethylepoxyquinomicin suppresses osteoclastogenesis and expression of NFATc1 in mouse arthritis without affecting expression of RANKL, osteoprotegerin or macrophage colony-stimulating factor.
    Kubota T; Hoshino M; Aoki K; Ohya K; Komano Y; Nanki T; Miyasaka N; Umezawa K
    Arthritis Res Ther; 2007; 9(5):R97. PubMed ID: 17892600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DHMEQ, a novel NF-kappaB inhibitor, suppresses growth and type I collagen accumulation in keloid fibroblasts.
    Makino S; Mitsutake N; Nakashima M; Saenko VA; Ohtsuru A; Umezawa K; Tanaka K; Hirano A; Yamashita S
    J Dermatol Sci; 2008 Sep; 51(3):171-80. PubMed ID: 18406579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of thyroid cancer cell apoptosis by a novel nuclear factor kappaB inhibitor, dehydroxymethylepoxyquinomicin.
    Starenki DV; Namba H; Saenko VA; Ohtsuru A; Maeda S; Umezawa K; Yamashita S
    Clin Cancer Res; 2004 Oct; 10(20):6821-9. PubMed ID: 15501958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.